Project Grant R44CA310402
Award Date 9/16/25
Completion Date 8/31/27
Dollars Obligated $1.1M
Federal Agency
Awardee
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Morrisville, NC, USA
Similar Awards
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $1,031,566 to Mucommune LLC to develop in vivo-engineered B7-H3 chimeric antigen receptor (CAR) T-cells for ovarian cancer therapy. The project aims to leverage a novel viral vector system to directly engineer circulating T-cells in the body, rather than harvesting, modifying, and expanding them ex vivo. This approach has the potential to reduce the time and cost of CAR-T therapy...
- This Project Grant, awarded by the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), funds the development and validation of a novel armored CAR-T immunotherapeutic for the treatment of pancreatic ductal adenocarcinoma (PDAC). The $400,835 award to Cambium Oncology LLC aims to engineer CAR-T cells that can secrete a VIP receptor antagonist to disrupt the immunosuppressive tumor microenvironment in PDAC. The 1-year project involves developing and validating...
- This $118,722 Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) supports research to develop a novel immunotherapy for pancreatic cancer. The grant funding will be used by Emory University to engineer CD4+ T cells expressing high levels of the enzyme CD26 and equip them with a chimeric antigen receptor (CAR) targeting mesothelin, a protein expressed on pancreatic tumor cells. The research aims to harness the favorable properties of CD26+ T cells to...
- The federal Project Grant award of $627,272 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to The Johns Hopkins University aims to optimize the efficacy of CAR T cells against pancreatic tumors using engineered, synthetic cytokine receptors (velocity receptors, VRs) that enhance CAR T migration speed and tumor infiltration. The project will test the motility and cell-killing capability of these new CAR T cells in vitro, and then select and validate the ten most...
- The U.S. National Cancer Institute (NCI) has awarded a $398,997 Project Grant under the Cancer Treatment Research federal grant program (CFDA 93.395) to Immunogenik, Inc. to enhance cancer therapeutics with a novel 3-in-1 chimeric antigen receptor (CAR) T cell approach. The research aims to target tumor-associated myeloid cells, which can suppress anti-tumor immune responses, by inhibiting the immunosuppressive LAIR1 signaling pathway. Key deliverables include demonstrating the efficacy of LAIR1...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $400,000 to Kure Ai Inc. to develop a novel CAR-T cell therapy product targeting the MR1 antigen expressed on the surface of various tumor cells, including acute myeloid leukemia (AML) and glioblastoma. The key objectives are to: 1) assess MR1 expression in primary patient AML and glioblastoma samples, 2) perform mouse efficacy studies using AML and glioblastoma models, and 3)...
- This Project Grant award of $735,751.00, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports research conducted by the University of Texas MD Anderson Cancer Center to develop a novel immunotherapy approach for the treatment of pancreatic cancer. The research aims to combine TROP2-directed chimeric antigen receptor (CAR) natural killer (NK) cells with hypoxia-inducible factor 2 alpha (HIF2a) inhibition, with the goal of...
- The National Cancer Institute awarded a $119,858 Project Grant under the Cancer Biology Research program (CFDA 93.396) to the Regents of the University of Minnesota, Office of Sponsored Projects Administration. The award supports research to elucidate mechanisms governing immune surveillance and resistance to antitumor T cell response in pancreatic cancer. The project aims to identify ways to safely promote T cell-mediated destruction of pancreatic cancer through combinatorial immunotherapies....
- The National Cancer Institute awarded a $176,040 Project Grant to The General Hospital Corporation (Massachusetts General Hospital) from July 1, 2025 to June 30, 2027 under the Cancer Research Manpower (CFDA 93.398) federal grant program. The goal of this project is to develop new strategies to engineer CAR-T cells that can overcome the cancer cell glycocalyx barrier in solid tumors. This will involve: (1) engineering CAR-T cells to strengthen the immune synapse by enhancing binding to the...
- The federal Project Grant award titled "HARNESSING B CELLS AFTER STEM CELL TRANSPLANT TO PRODUCE NOVEL CAR-TS" is funded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) for a total of $415,257. The project period runs from July 3, 2025 to June 30, 2027. The award aims to leverage insights into B cell tolerance mechanisms after hematopoietic stem cell transplantation to engineer less toxic, more targeted immune cells that can eradicate hematological...